Phase II Trial of Pramipexole vs Escitalopram for MDD in HIV Patients
A phase II trial is underway comparing pramipexole ER and escitalopram for treating MDD in HIV patients.
Asset / Drug
Drug and asset intelligence for Pramipexole with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.